Internal Medicine, Infectious Disease · New York, NY
NPI
1730107574
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
5 E 98th St
New York, NY, 10029
Phone (212) 241-3150
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
343 services
Medicare patients, 2024
143
Average age 70
Drug cost, 2024
$8.1M
7,968 prescriptions
Company payments, 2025
$114
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael P Mullen was code 99214 (office e&m - established), 301 times for 125 patients. In total Michael P Mullen billed 343 services in 8 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 301 | 125 | $70.70 | $21K |
| 99213 Office E&M - Established | Office | 17 | 12 | $53.94 | $917 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 14 | 14 | $143.97 | $2,016 |
By year: 2022 $52K for 857 services; 2023 $46K for 726 services; 2024 $25K for 343 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 218 | 122 | $8.32 | $1,815 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael P Mullen prescribed most often to Medicare patients was Descovy (Emtricitabine/Tenofov Alafenam), with 572 prescriptions and refills. In total Michael P Mullen wrote 7,968 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | 572 | 638 | 63 | $1.4M |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 379 | 383 | 38 | $1.6M |
| Rosuvastatin Calcium Generic | 376 | 717 | 73 | $3,036 |
| Tivicay Dolutegravir Sodium | 346 | 380 | 36 | $969K |
| Isentress Raltegravir Potassium | 226 | 226 | 21 | $453K |
| Ritonavir Generic | 218 | 278 | 25 | $43K |
| Darunavir Generic | 192 | 192 | 19 | $163K |
| Atorvastatin Calcium Generic | 190 | 396 | 43 | $1,087 |
| Acyclovir Generic | 154 | 229 | 27 | $2,052 |
| Prezcobix Darunavir/Cobicistat | 152 | 178 | 17 | $435K |
| Valacyclovir Valacyclovir Hcl | 151 | 252 | 37 | $6,595 |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 140 | 156 | 16 | $567K |
| Amlodipine Besylate Generic | 128 | 273 | 28 | $364 |
| Hydrochlorothiazide Generic | 127 | 236 | 24 | $429 |
| Telmisartan Generic | 114 | 226 | 23 | $2,214 |
Brand drugs: 2,765 claims; generic drugs: 5,139 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael P Mullen $114 ($114 in general payments such as food, travel and fees) from 2 companies. The largest payer was Theratechnologies Inc. with $86.27.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.